First and only oral therapy approved for mild, moderate, and severe plaque psoriasis, and active PsA SEE THE DATA

Plaque Psoriasis
3 INDICATIONS Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. Read more
*Estimates of patients treated reflect global data since launch (Apr 2014-Aug 2022; US=approximately 60% of data). Calculations based on observed drug utilization parameters and number of units distributed. Utilization patterns change over time to best represent current markets.
FDA, U.S. Food and Drug Administration; PsA, psoriatic arthritis; TB, tuberculosis.
References: 1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 2. Data on file, Amgen Inc. 3. Otezla® (apremilast) FDA approval letter. March 21, 2014.
Actual Otezla patient. 1 Individual results may vary.
*PASI-49.7 response: A 49.7% reduction in a patient’s PASI score. 1
Actual clinical trial patient from ESTEEM. 1 Individual results may vary.
†PASI-52 response: A 52% reduction in a patient’s PASI score. 1
Actual Otezla patient. 1 Individual results may vary.
‡PASI-62.5 response: A 62.5% reduction in a patient’s PASI score. 1
§PASI-72 response: A 72% reduction in a patient’s PASI score. 1
Actual clinical trial patient from ESTEEM. 1 Individual results may vary.
**PASI-63 response: A 63% reduction in a patient’s PASI score. 1
Actual clinical trial patient from ESTEEM. 1 Individual results may vary.
††PASI-69 response: A 69% reduction in a patient’s PASI score. 1
Actual clinical trial patient from ESTEEM. 1 Individual results may vary.
‡‡PASI-70 response: A 70% reduction in a patient’s PASI score. 1
Actual Otezla patient. 1 Individual results may vary.
§§PASI-75 response: A 75% reduction in a patient’s PASI score. 1
Actual Otezla patient. 1 Individual results may vary.
***PASI-76.5 response: A 76.5% reduction in a patient’s PASI score. 1
†††PASI-90 response: A 90% reduction in a patient’s PASI score. 1
Actual Otezla patient. 1 Images are not reflective of NAPSI score. Individual results may vary.
Actual Otezla patient. 1 Images are not reflective of NAPSI score. Individual results may vary.
Actual Otezla patient. 1 Individual results may vary.
‡‡‡PASI-80 response: An 80% reduction in a patient’s PASI score. 1
Actual Otezla patient. 1 Individual results may vary.
Actual clinical trial patient from ESTEEM. 1 Individual results may vary.
§§§PASI-85 response: An 85% reduction in a patient’s PASI score. 1
Actual clinical trial patient from STYLE. 1
Individual results may
vary.
Actual clinical trial patient from STYLE. 1
Individual results may
vary.
Actual clinical trial patient from STYLE. 1 Individual results may vary.
Actual clinical trial patient from DISCREET. 1 Individual results may vary.
NAPSI, Nail Psoriasis Severity Index; PASI, Psoriasis Area and Severity Index; ScPGA, Scalp Physician Global Assessment.
Contraindications
Warnings and Precautions
Adverse Reactions
Use in Specific Populations
Please click here for the full Prescribing Information.
Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for
phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Reference: 1. Data on file, Amgen Inc.